New - Highly Purified, Cost-Effective CMV Native Antigen for IgM
The Native Antigen Company has announced the release of a highly purified Cytomegalovirus (CMV) native antigen.
The antigen has been manufactured in response to the in-vitro diagnostics (IVD) industry’s requirement for a cost effective antigen which can demonstrate a high affinity for not only IgG but more importantly, for IgM.
This latest antigen from NAC’s rapidly increasing portfolio also minimizes cross-reactivity and lot to lot variation.
The company is well equipped to meet an anticipated high volume requirement from IVD manufacturers who major in this field.
Presently, CMV infection is mostly controlled in immune compromised patients by available antiviral drugs, yet it continues to maintain its role as one of the most dangerous infectious agents for the unborn infant.
Primary infection is consistently associated with the presence of a virus specific IgM antibody response.
Use of NAC’s CMV purified native antigen will aid in improving serology based assays for early detection.